SYTL2

Across TCGA pan-cancer cohorts, SYTL2 mass-spec protein is linked to patient survival in 3 of 34 cancer types, making it a survival-associated SYTL2 data layer compared with 26 for mass-spec protein and 5 for mutation status.

The strongest signal is observed in pancreatic ductal adenocarcinoma (PDAC), where higher SYTL2 mass-spec protein is associated with better overall survival. In most high-consensus cancer types, elevated SYTL2 expression acts as an unfavorable survival marker, although some lineages such as PDAC and LUAD show a favorable association.

PDAC, CCRCC, and LUAD are the cancer types where SYTL2 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
PDAC	OS	Median	III,IV	0.639	0.275	.001	70	view →
CCRCC	DFS	Median	IV	0.220	0.781	.017	7	view →
LUAD	OS	Median	All	0.971	0.914	.031	3	view →

Pink = unfavorable, green = favorable. Showing the 3 strongest of 3 lineages.

SYTL2–PDAC (OS)

Open the PDAC breakdown →